Senores Pharmaceuticals Q4 FY26: income up 66% to ₹190 cr

Stock snapshot: price, day range, and 52-week band

Senores Pharmaceuticals (NSE: SENORES) was at ₹932.55 as of 14 May, 2026 (14:29 IST), down ₹41.20 (-4.23%). The move came even as the stock remained close to its 52-week peak levels.

During the session, the stock traded in an intraday range of ₹925.00 to ₹990.55. Over the last 52 weeks, the price has fluctuated between ₹491.00 and ₹991.00, placing the day’s highs near the upper end of the annual range.

The price action matters because it frames how the market is responding to the company’s latest financial update and corporate developments. With the stock hovering near its 52-week high, incremental news flow tends to be reflected quickly in trading.

Board meeting outcome: audited results on the agenda

A board update titled “Outcome of Board Meeting held on May 14, 2026” noted that Senores Pharmaceuticals announced Q4 FY26 and full-year FY26 consolidated financial results. The board meeting was scheduled for May 14, 2026, with the primary agenda to consider and approve audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026.

The update is significant because audited numbers are generally treated as a firmer reference point for investors than periodic operational commentary. It also provides a timely checkpoint on profitability, especially after rapid growth phases.

Q4 FY26: total income, EBITDA, and PAT jump

For Q4 FY26, the company reported strong growth across the key profit and loss lines:

• Total income grew 66% to ₹190 crore
• EBITDA surged 219% to ₹62 crore
• PAT increased 104% to ₹37 crore

The combination of higher income growth and a sharper rise in EBITDA suggests that profitability scaled materially during the quarter. The reported PAT growth indicates that the improvement flowed through after operating costs and other expenses.

While the excerpt flags “full-year FY26” results as well, only Q4 FY26 headline numbers are explicitly stated in the provided disclosure. Investors typically look for full-year bridges and segment-level details in the detailed filing to assess whether quarterly strength reflects one-off factors or a broader trend.

Corporate actions: Apnar acquisition and Amerisyn JV

Alongside the results update, Senores Pharmaceuticals disclosed two corporate developments:

1. The company completed a 75% stake acquisition in Apnar Pharmaceuticals.
2. It formed a 70% joint venture, Amerisyn, for the US federal market.

Both items point to an expansion effort beyond routine filings. A majority acquisition can change consolidation and earnings mix, while a US federal market-focused JV suggests a targeted route to participate in a specific regulated procurement channel.

What the company had said earlier: FY25 operating context

In an earnings call dated May 16, 2025 (Q4 FY2025), Senores outlined performance and strategy that provide context for the FY26 quarter update.

The company said it expanded its ANDA portfolio in regulated markets and maintained an annual margin range of 24% to 26% as a sustainable band. Segment-wise for Q4 FY2025, it reported income from the regulated market rising 17% to ₹64 crore, while emerging markets income was about ₹37 crore.

For the full year FY2025, it stated total income of ₹410 crore, reflecting 91% growth over FY2024. It also reported regulated market income of about ₹245 crore (up about 69%) and emerging markets income of about ₹121 crore (a 1704% growth over FY2024, as stated in the call).

The company also reported FY2025 consolidated EBITDA of about ₹102 crore (up 145%) with an EBITDA margin of about 25%, and profit after tax and minority interest of about ₹59 crore (up 86%).

Other reported financial snapshots in filings

A financial results table (amounts originally stated in lakhs) shows the following quarterly numbers. (Converted here to ₹ crore for consistency, where 1 crore = 100 lakhs.)

Separately, a data panel labelled 202506 reported: Revenue ₹15.49 crore, EBITDA ₹7.22 crore, net income ₹2.70 crore, net profit margin 17.43%, EPS 0.59, and an effective tax rate 24.79%.

Key facts at a glance

Market impact: how investors may read the mix of numbers

On the day of the update, the stock traded lower even as the quarter’s reported growth rates were strong. With the price close to the 52-week high band, short-term trading can reflect positioning, profit-taking, or expectations already priced in.

From an investor’s perspective, Q4 FY26’s sharp EBITDA jump is a focal point because operating leverage and margin expansion often influence valuation and earnings confidence. At the same time, the corporate actions around Apnar and the Amerisyn JV add integration and execution considerations that investors typically monitor over subsequent quarters.

The “MC Essentials” snapshot also lists strengths and risks such as good quarterly growth and a note on RoCE declining, plus a “Threats” flag for high PE (PE > 40). These are qualitative signals rather than audited metrics, but they reflect common market lenses applied to fast-growing pharma names.

Analysis: why the May 14 disclosure matters

The May 14, 2026 disclosure combines three decision-useful elements in one event: audited results approval, a strong quarter on headline profitability, and a pair of deal-related updates. Together, these points can influence how investors assess sustainability of earnings and the direction of business expansion.

The FY25 commentary in the earnings call shows the company has been tracking regulated and emerging market performance separately and maintaining a stated margin range. The Q4 FY26 quarter update, with much faster EBITDA growth than income growth, signals a quarter where costs and operating profile moved favourably.

For the market, the key follow-up is usually the detailed audited filing, which clarifies the full-year FY26 bridge, the impact of acquisitions and JVs on consolidation, and the quality of earnings across segments.

Conclusion

Senores Pharmaceuticals reported Q4 FY26 total income of ₹190 crore, EBITDA of ₹62 crore, and PAT of ₹37 crore, alongside completion of a 75% acquisition in Apnar Pharmaceuticals and the formation of a 70% JV, Amerisyn, for the US federal market. The stock was down 4.23% at ₹932.55 on May 14, 2026, trading within ₹925.00 to ₹990.55 and near its ₹991.00 52-week high.

Next, investor attention typically shifts to the full audited financial statements for the year ended March 31, 2026, and any additional disclosures that explain segment performance and the financial impact of the newly announced corporate moves.